Duncan Sze-Tu, MD
Family Medicine · Endwell, NYNPI 1467472647
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 94 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Novo Nordisk at 25.2% of the total. Reporting peaked in 2023 at $456 and has fallen 57.7% since, to $193 in 2025.
Across 94 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$386
- AbbVie$113
- Lilly USA, LLC$105
- Pfizer$87
- GSK$72
- Verona Pharma, Inc.$67
- plus $701 from 22 others
Across 75 payments — averaging $3134.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$137K
- Biohaven Pharmaceuticals, Inc.$65K
- Eli Lilly$19K
- Biohaven Pharmaceutical Holding Company Ltd.$14K
What the payments were for
- Food & beverage$1,530100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $386 |
| AbbVie | 5 | $113 |
| Lilly USA, LLC | 6 | $105 |
| Pfizer | 6 | $87 |
| GSK | 5 | $72 |
| Verona Pharma, Inc. | 3 | $67 |
| Novartis | 4 | $60 |
| Amgen | 4 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $55 |
| Merck | 3 | $54 |
| Corcept Therapeutics | 3 | $46 |
| Edwards Lifesciences | 1 | $46 |
| Irhythm Technologies, Inc. | 1 | $38 |
| Abbott | 3 | $36 |
| Boehringer Ingelheim | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| AstraZeneca | 1 | $29 |
| Astellas Pharma US Inc | 1 | $25 |
| Johnson & Johnson | 1 | $25 |
| Nevro Corp. | 1 | $24 |
| Corium, LLC | 2 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Gilead | 1 | $14 |
| Si-bone, Inc. | 2 | $14 |
| Exact Sciences | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Neuronetics, Inc. | 1 | $10 |
How this compares
$1,530 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 68 | $72,334 |
| OzempicSemaglutide | 34 | $44,599 |
| JanuviaSitagliptin Phosphate | 40 | $42,120 |
| JardianceEmpagliflozin | 18 | $24,499 |
| RybelsusSemaglutide | 16 | $22,157 |
| Repatha SureclickEvolocumab | 14 | $14,871 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $13,835 |
| Atorvastatin Calcium | 660 | $8,367 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $8,056 |
| Metoprolol Succinate | 121 | $3,775 |
| Potassium Chloride | 37 | $3,202 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $2,575 |
| Lisinopril | 327 | $2,369 |
| Rosuvastatin Calcium | 140 | $2,195 |
| Tamsulosin Hcl | 98 | $2,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $87 | $72,33468 claims |
| Novo NordiskOzempic, Rybelsus | $386 | $66,75650 claims |
| MerckJanuvia | $54 | $42,12040 claims |
| Boehringer IngelheimJardiance | $35 | $24,49918 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $72 | $21,89140 claims |
| AbbVieSynthroid | $113 | $1,05715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.
Other family medicine in Endwell
- Louis BonavitaEast Syracuse$674K
- Martin MahoneyBuffalo$520K
- Scott BrehautClinton$514K
- David St PeterSaratoga Springs$395K
- Matthew PabisNew York$222K
- Rajveer SachdevPomona$211K
- Eric SchnakenbergHalfmoon$190K
- James NorthGlens Falls$186K
- Eric BatesNew York$171K
- Alexander BlinskiNew York$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.